Decreto 472 of 1994: How the Venezuela SACS Structure Arose

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The current Venezuelan sanitary supervision system traces back to Decreto N° 472 of December 27, 1994. That decree ordered the creation of the General Sectoral Directorate of Sanitary Control (Dirección General Sectorial de Contraloría Sanitaria), with a unified mandate covering the registration, supervision and inspection of medicines, cosmetics, food and beverages, equipment, buildings and health professions.

The value of understanding this lineage is that it explains why medical devices and medicines sit in two separate directorate channels inside SACS. The original institutional design cut the field horizontally by broad product family, not vertically by risk level. That structural choice, made more than three decades ago, still determines which filing path a product must take today.

For an applicant the lineage is not antiquarian detail. Historic certificates, historic file numbers and historic unit names all refer to the same functional system under different labels, and a reviewer reading an old file will map it onto the current structure without difficulty. A company that cannot perform the same mapping will misjudge whether an old registration is still the relevant predecessor of the current one, or whether it lapsed and was replaced by a fresh filing.

2. Legal basis

InstrumentReference numberPublication dateArticle / key point
Decreto N° 472Decreto N° 472December 27, 1994Creates the General Sectoral Directorate of Sanitary Control, with unified responsibility for registration, supervision and inspection across several product families
Reglamento Orgánico del MPPSGaceta Oficial N° 38.591December 26, 2006Subsequent organizational regulation adjusting the directorate structure
Circular N° DGSACS/0002/2025DGSACS/0002/2025October 28, 2025Platform-based adjustment of the current procedural entry points

3. Expert insights

Insight 1: the institutional history explains where the horizontal split came from. The original design under Decreto N° 472 grouped medicines and cosmetics in one direction and food in another, while medical devices and auxiliary equipment were given a separate registration and control office (OICEMP). That product-family architecture has survived to the present and produced the arrangement of parallel directorates inside SACS, which is why a device file and a medicine file never share a reviewer even when the products are clinically adjacent.

Insight 2: the partial and then suspended relationship with the Andean Community and Mercosur shaped where technical standards come from. Venezuela joined Mercosur in 2005, but its membership has been suspended indefinitely since 2017. The stagnation of regional harmonization means that Venezuelan device requirements rely more on domestic temporary administrative instructions than on regionally agreed technical regulations. A company that expects a harmonized regional dossier to satisfy a Venezuelan reviewer is relying on an assumption that the institutional record does not support.

Insight 3: the stability of the institution’s name is lower than the stability of its functions. From the general directorate of 1994 to today’s autonomous service (SACS), the body has been upgraded in status to an autonomous service, but the core functions of registration, supervision and inspection have not changed. When searching historical records, different institutional names encountered at different periods should be read as different stages of one functional system, not as different authorities.

The product-family logic also explains a pattern that otherwise looks arbitrary to outside applicants: why a manufacturer with a single portfolio may need several filing streams, and why a company that has registered a medicine cannot assume that its device will travel through the same channel. The division was designed for administrative load balancing across product families, not for the convenience of an applicant whose portfolio spans several of them.

There is one more consequence worth flagging for due diligence. Because the mandate of the 1994 directorate was unified across medicines, cosmetics, food, equipment, buildings and health professions, early records may describe a device in the vocabulary of a different product family. A historic file that calls an item equipment or material, rather than a medical device, is not necessarily an error; it may reflect the classification vocabulary in force when the file was opened. Reading such a file correctly requires knowing which vocabulary belonged to which period.

The practical reading of all three insights is the same. Structure has been more durable than nomenclature, and nomenclature has been more durable than the rules applied inside it. A due-diligence exercise that establishes the current unit, the historic unit and the continuity of the file between them will rarely be surprised by a change of name, whereas an exercise that treats each name as a new authority will repeatedly restart its research from zero.

4. Practical recommendations

  1. When reviewing historical registration files, note the institutional name used at the time, so that an apparent mismatch of names is not mistaken for a defect in the validity of the file.
  2. When confirming the intake window, use the broad product family as the first dimension of judgment rather than the risk class, because the organizational structure is built on the former.
  3. For an existing certificate, require the holder to produce evidence of the complete chain of lineage, including whether the file passed through an institutional reorganization and whether the certificate was reissued.
  4. Monitor changes in regional integration status. If the Mercosur membership position changes, the source of technical standards may shift with it, and dossier assumptions built on domestic instructions may need to be revisited.

5. Verification checklist

  • □ Confirmed the current directorate name applicable to this product, in the materials and equipment channel
  • □ Confirmed the correspondence between the old institutional names in the historic file and the current structure
  • □ Confirmed whether the existing certificate has been reissued or re-registered at any point
  • □ Confirmed whether the Mercosur membership status affects the source of technical requirements for this product
  • □ Re-checked whether Decreto N° 472 has been substantively replaced by a later organizational regulation

Regulatory information verified as of October 29, 2026.

For a Venezuela market-entry feasibility assessment covering your specific product, contact the GRZAN regulatory team. GRZAN supports manufacturers, importers and authorized representatives with device registration in Venezuela: reconstructing the lineage of existing registrations, confirming the current directorate and department, and preparing files that survive review under the present organizational structure. Reach us at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail